Amylyx Pharmaceuticals (AMLX) Competitors

Amylyx Pharmaceuticals (NASDAQ:AMLX) and Ultragenyx Pharmaceutical (NASDAQ:RARE) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their earnings, media sentiment, dividends, profitability, institutional ownership, analyst recommendations, risk and valuation.

Does the media favor AMLX or RARE?

In the previous week, Ultragenyx Pharmaceutical had 39 more articles in the media than Amylyx Pharmaceuticals. MarketBeat recorded 48 mentions for Ultragenyx Pharmaceutical and 9 mentions for Amylyx Pharmaceuticals. Amylyx Pharmaceuticals' average media sentiment score of 0.27 beat Ultragenyx Pharmaceutical's score of 0.26 indicating that Amylyx Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Amylyx Pharmaceuticals	1 Very Positive mention(s)	2 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Ultragenyx Pharmaceutical	12 Very Positive mention(s)	2 Positive mention(s)	7 Neutral mention(s)	2 Negative mention(s)	1 Very Negative mention(s)	Neutral

Which has more volatility & risk, AMLX or RARE?

Amylyx Pharmaceuticals has a beta of -0.46, meaning that its stock price is 146% less volatile than the S&P 500. Comparatively, Ultragenyx Pharmaceutical has a beta of 0.25, meaning that its stock price is 75% less volatile than the S&P 500.

Do institutionals and insiders have more ownership in AMLX or RARE?

95.8% of Amylyx Pharmaceuticals shares are held by institutional investors. Comparatively, 97.7% of Ultragenyx Pharmaceutical shares are held by institutional investors. 12.3% of Amylyx Pharmaceuticals shares are held by company insiders. Comparatively, 5.5% of Ultragenyx Pharmaceutical shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Do analysts prefer AMLX or RARE?

Amylyx Pharmaceuticals currently has a consensus target price of $11.75, suggesting a potential upside of 39.71%. Ultragenyx Pharmaceutical has a consensus target price of $81.50, suggesting a potential upside of 180.94%. Given Ultragenyx Pharmaceutical's higher possible upside, analysts clearly believe Ultragenyx Pharmaceutical is more favorable than Amylyx Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Amylyx Pharmaceuticals	0 Sell rating(s)	2 Hold rating(s)	9 Buy rating(s)	2 Strong Buy rating(s)	3.00
Ultragenyx Pharmaceutical	0 Sell rating(s)	1 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.92

Is AMLX or RARE more profitable?

Amylyx Pharmaceuticals has a net margin of 0.00% compared to Ultragenyx Pharmaceutical's net margin of -87.34%. Amylyx Pharmaceuticals' return on equity of -82.48% beat Ultragenyx Pharmaceutical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Amylyx Pharmaceuticals	N/A	-82.48%	-70.15%
Ultragenyx Pharmaceutical	-87.34%	-237.48%	-37.66%

Which has stronger earnings & valuation, AMLX or RARE?

Amylyx Pharmaceuticals has higher earnings, but lower revenue than Ultragenyx Pharmaceutical. Ultragenyx Pharmaceutical is trading at a lower price-to-earnings ratio than Amylyx Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Amylyx Pharmaceuticals	-$249K	-3,011.62	-$301.74M	-$2.50	-3.36
Ultragenyx Pharmaceutical	$560.23M	4.99	-$569.18M	-$5.53	-5.25

Summary

Amylyx Pharmaceuticals beats Ultragenyx Pharmaceutical on 9 of the 17 factors compared between the two stocks.